Hydrops fetalis

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Hydrops fetalis
Ultrasound Scan ND 373.jpg
An ultrasound showing a fetus with Hydrops fetalis
SpecialtyObstetrics and gynaecology, hematology, immunology Edit this on Wikidata

Hydrops fetalis is a condition in the fetus characterized by an accumulation of fluid, or edema, in at least two fetal compartments.[1] By comparison, hydrops allantois or hydrops amnion is an accumulation of excessive fluid in the allantoic or amniotic space, respectively.[2]

Signs and symptoms[edit]

Locations can include the subcutaneous tissue on the scalp, the pleura (pleural effusion), the pericardium (pericardial effusion) and the abdomen (ascites). Edema is usually seen in the fetal subcutaneous tissue, sometimes leading to spontaneous abortion. It is a prenatal form of heart failure, in which the heart is unable to satisfy demand (in most cases abnormally high) for blood flow.[citation needed]

Causes[edit]

Hydrops fetalis usually stems from fetal anemia, when the heart needs to pump a much greater volume of blood to deliver the same amount of oxygen. This anemia can have either an immune or non-immune cause. Non-immune hydrops can also be unrelated to anemia, for example if a fetal tumor or congenital cystic adenomatoid malformation increases the demand for blood flow.[3] The increased demand for cardiac output leads to heart failure, and corresponding edema.

Immune Pathophysiology[edit]

Rh disease is the only immune cause of hydrops fetalis. Erythroblastosis fetalis, also known as Rh disease, is a hemolytic disease of newborns. Pregnant mothers do not always have the same blood type as their child. During birth or throughout the pregnancy, the mother may be exposed to the infant's blood. In the event of a pregnancy where the fetus has the Rh-D blood antigen and the mother does not, the mother's immune system will respond to the red blood cells as foreign and create antibodies against the Rh-D antigen on the fetal blood cells. Rh disease develops in the event of a second pregnancy where the mother's immune system launches an attack, via IgG, against the infant's Rh-D positive blood cells. The immune response results in hemolysis of fetal red blood cells causing severe anemia.[citation needed]

Hemolysis caused by the Rh incompatibility, causes extramedullary hematopoiesis in the fetal liver and bone marrow.[4] The push to make more erythroblasts to help compensate with the hemolysis over works the liver causing hepatomegaly. The resulting liver dysfunction decreases albumin output which in turn decreases oncotic pressure. Consequentially, the decrease in pressure results in overall peripheral edema and ascites.[citation needed]

Rh disease is currently an uncommon cause of immune-mediated hydrops fetalis. Due to preventative methods developed in the 1970s, the incidence of Rh disease has markedly declined. Rh disease can be prevented by administration of anti-D IgG (Rho(D) Immune Globulin) injections to RhD-negative mothers during pregnancy and/or within 72 hours of the delivery. However, a small percentage of pregnant mothers are still susceptible to Rh disease even after receiving anti-D IgG (Rho(D) Immune Globulin)[citation needed]

Non-immune Pathophysiology[edit]

Severe anemia leads to hyper dynamic circulation, which means high-output cardiac failure causes the blood to circulate rapidly. The excessive pumping of blood causes the left side of the heart to fail leading to pulmonary edema. The build up of fluid in the lungs increases the pressure in the lungs leading to vasoconstriction. The coupled vasoconstriction and pulmonary hypertension causes the right side of the heart to fail which in turn, increases the venous hydrostatic pressure in the body. The summation of these effects ultimately leads to peripheral edema and ascites. All in all, the left side failure of the heart will lead to pulmonary edema whereas right side failure will lead to peripheral edema and ascites. The non-immune form of hydrops fetalis has many causes including:[5][6]

Diagnosis[edit]

Hydrops fetalis can be diagnosed and monitored by ultrasound scans. An official diagnosis is made by identifying excess serous fluid in at least one space (ascites, pleural effusion, of pericardial effusion) accompanied by skin edema (greater than 5 mm thick). A diagnosis can also be made by identifying excess serous fluid in two potential spaces without accompanying edema. Prenatal ultrasound scanning enables early recognition of hydrops fetalis and has been enhanced with the introduction of MCA Doppler.[5]

Treatment[edit]

The treatment depends on the cause and stage of the pregnancy.[5]

  • Severely anemic fetuses, including those with Rh disease and alpha thalassemia major, can be treated with blood transfusions while still in the womb. This treatment increases the chance that the fetus will survive until birth.[5][8][9]
  • Therapy for Cardiac tachyarrhythmia, supraventricular tachycardia, atrial flutter, or atrial fibrillation etiologies are maternal transplacental administration of antiarrhythmic medication(s). This type of treatment is recommended unless the fetus is close to term.[10]
  • Therapy for Fetal anemia caused by a parvovirus infection or fetomaternal hemorrhage is fetal blood sampling followed by intrauterine transfusion. This treatment at an advanced gestational age poses risks and should not be performed if the risks associated with delivery are considered to be less than those associated with the procedure.[11]
  • Fetal hydrothorax, chylothorax, or large pleural effusion associated with bronchopulmonary sequestration should be treated using a Fetal needle drainage of effusion or placement of thoracoamniotic shunt. This procedure can be performed prior to delivery if gestational age is advanced.[12]
  • Hydrops Fetalis resulting from fetal CPAM can be treated using either a fetal needle drainage of effusion or placement of thoracoamniotic shunt or a maternal administration of corticosteroids, betamethasone 12.5 mg IM q24 h × 2 doses or dexamethasone 6.25 mg IM q12 h × 4 doses.[13]
  • Therapy for hydrops fetalis derived from TTTS or TAPS requires laser ablation of placental anastomoses or selective termination.[14]
  • Therapy for hydrops fetalis derived from TRAPS requires percutaneous radio frequency ablation.[15]

See also[edit]

References[edit]

  1. ^ "Hydrops Fetalis: eMedicine Pediatrics: Cardiac Disease and Critical Care Medicine". Retrieved 2010-02-11.
  2. ^ Knottenbelt, Derek C. (2003). Equine stud farm medicine and surgery. ISBN 9780702021305. Retrieved 2010-02-11.
  3. ^ Isaacs, Hart (January 2008). "Fetal hydrops associated with tumors". American Journal of Perinatology. 25 (1): 43–68. doi:10.1055/s-2007-1004826. ISSN 0735-1631. PMID 18075961.
  4. ^ Jagannathan-Bogdan, Madhumita; Zon, Leonard I. (2013-06-15). "Hematopoiesis". Development. 140 (12): 2463–2467. doi:10.1242/dev.083147. ISSN 0950-1991. PMC 3666375. PMID 23715539.
  5. ^ a b c d Norton, Mary E.; Chauhan, Suneet P.; Dashe, Jodi S. (February 2015). "Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline #7: nonimmune hydrops fetalis". American Journal of Obstetrics and Gynecology. 212 (2): 127–139. doi:10.1016/j.ajog.2014.12.018. ISSN 0002-9378. PMID 25557883.
  6. ^ Nassr, Ahmed A.; Ness, Amen; Hosseinzadeh, Pardis; Salmanian, Bahram; Espinoza, Jimmy; Berger, Victoria; Werner, Eleonore; Erfani, Hadi; Welty, Stephen; Bateni, Zhoobin H.; Shamshirsaz, Amir A. (2018). "Outcome and Treatment of Antenatally Diagnosed Nonimmune Hydrops Fetalis". Fetal Diagnosis and Therapy. 43 (2): 123–128. doi:10.1159/000475990. ISSN 1015-3837. PMID 28647738. S2CID 3601812.
  7. ^ Isaacs, Hart (January 2008). "Fetal Hydrops Associated with Tumors". American Journal of Perinatology. 25 (1): 043–068. doi:10.1055/s-2007-1004826. ISSN 0735-1631. PMID 18075961.
  8. ^ Vichinsky, Elliott P. (2009-01-01). "Alpha thalassemia major—new mutations, intrauterine management, and outcomes". Hematology. 2009 (1): 35–41. doi:10.1182/asheducation-2009.1.35. ISSN 1520-4391. PMID 20008180.
  9. ^ Derderian, S. Christopher; Jeanty, Cerine; Fleck, Shannon R.; Cheng, Lily S.; Peyvandi, Shabnam; Moon-Grady, Anita J.; Farrell, Jody; Hirose, Shinjiro; Gonzalez, Juan; Keller, Roberta L.; MacKenzie, Tippi C. (January 2015). "The many faces of hydrops". Journal of Pediatric Surgery. 50 (1): 50–54. doi:10.1016/j.jpedsurg.2014.10.027. ISSN 0022-3468. PMC 4315667. PMID 25598092.
  10. ^ Donofrio, Mary T.; Moon-Grady, Anita J.; Hornberger, Lisa K.; Copel, Joshua A.; Sklansky, Mark S.; Abuhamad, Alfred; Cuneo, Bettina F.; Huhta, James C.; Jonas, Richard A.; Krishnan, Anita; Lacey, Stephanie (2014-05-27). "Diagnosis and Treatment of Fetal Cardiac Disease: A Scientific Statement From the American Heart Association". Circulation. 129 (21): 2183–2242. doi:10.1161/01.cir.0000437597.44550.5d. ISSN 0009-7322. PMID 24763516.
  11. ^ Centers for Disease Control (CDC) (1989-02-17). "Risks associated with human parvovirus B19 infection". MMWR. Morbidity and Mortality Weekly Report. 38 (6): 81–88, 93–97. ISSN 0149-2195. PMID 2536885.
  12. ^ Yinon, Y.; Grisaru-Granovsky, S.; Chaddha, V.; Windrim, R.; Seaward, P. G. R.; Kelly, E. N.; Beresovska, O.; Ryan, G. (July 2010). "Perinatal outcome following fetal chest shunt insertion for pleural effusion". Ultrasound in Obstetrics & Gynecology. 36 (1): 58–64. doi:10.1002/uog.7507. ISSN 1469-0705. PMID 20069656. S2CID 206542529.
  13. ^ Wilson, R. Douglas; Baxter, Jason K.; Johnson, Mark P.; King, Mary; Kasperski, Stefanie; Crombleholme, Timothy M.; Flake, Alan W.; Hedrick, Holly L.; Howell, Lori J.; Adzick, N. Scott (2004). "Thoracoamniotic Shunts: Fetal Treatment of Pleural Effusions and Congenital Cystic Adenomatoid Malformations". Fetal Diagnosis and Therapy. 19 (5): 413–420. doi:10.1159/000078994. ISSN 1015-3837. PMID 15305098. S2CID 24586927.
  14. ^ Society for Maternal-Fetal Medicine; Simpson, Lynn L. (January 2013). "Twin-twin transfusion syndrome". American Journal of Obstetrics and Gynecology. 208 (1): 3–18. doi:10.1016/j.ajog.2012.10.880. ISSN 1097-6868. PMID 23200164. S2CID 78687065.
  15. ^ Lee, Hanmin; Bebbington, Michael; Crombleholme, Timothy M.; North American Fetal Therapy Network (2013). "The North American Fetal Therapy Network Registry data on outcomes of radiofrequency ablation for twin-reversed arterial perfusion sequence". Fetal Diagnosis and Therapy. 33 (4): 224–229. doi:10.1159/000343223. ISSN 1421-9964. PMID 23594603. S2CID 12699823.

External links[edit]

Classification
External resources